NCT04024891View on ClinicalTrials.gov

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

September 17, 2019

Study Completion Date

September 17, 2019

Conditions
MydriasisDilation
Interventions
DRUG

Phentolamine Mesylate Ophthalmic Solution 1%

1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

OTHER

Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

Topical Sterile Ophthalmic Solution

Trial Locations (4)

40517

Kentucky Eye Institute, Lexington

45701

Athens Eye Care, Athens

66762

Kannar Eye Care, Pittsburg

02888

West Bay Eye Associates, Warwick

Sponsors
All Listed Sponsors
lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT04024891 - Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis | Biotech Hunter | Biotech Hunter